Abstract
Allogeneic stem cell transplantation (SCT) is the treatment of choice for many hematological malignancies. Its curative graft-versus-leukemia (GvL) effect is mainly mediated by donor-derived alloreactive T cells. However, if the donor T cells are not selected for their reactivity against leukemic cells, the GvL effect is often associated with graft-versus-host disease (GvHD), a major complication of SCT. Here we summarize our current knowledge on leukemia-associated antigens and discuss strategies to apply minor and major histocompatibility antigens for cellular immunotherapy of hematological malignancies with a low risk of GvHD.
| Original language | English |
|---|---|
| Pages (from-to) | 23-31 |
| Number of pages | 9 |
| Journal | Seminars in Hematology |
| Volume | 39 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1 Jan 2002 |